Welcome to our dedicated page for Baxter International news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter International stock.
Baxter International Inc. (NYSE: BAX) is a global healthcare company dedicated to providing essential renal and hospital products. With a comprehensive portfolio that includes home, acute, and in-center dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition, biosurgery products, anesthetics, and pharmacy automation, Baxter plays a critical role in expanding access to healthcare worldwide.
Baxter's recent acquisition of Hillrom in late 2021 has significantly enhanced its hospital-focused offerings. This acquisition brought basic equipment like hospital beds under Baxter’s umbrella, along with advanced digital solutions such as smart beds and the Voalte medical communications app. These additions complement Baxter’s legacy operations, which focus on products for patients with acute and chronic kidney failure. Notably, Baxter plans to spin off its renal care segment by mid-2024.
Additionally, Baxter provides a variety of injectable therapies, including IV pumps, administrative sets, and nutritional products, as well as surgical sealants and hemostatic agents used in various care settings. The company’s extensive global footprint and the essential nature of its products and services underscore its commitment to advancing healthcare innovations and improving patient care in both emerging and developed markets.
Baxter’s financial condition remains robust, bolstered by its continuous innovation and strategic partnerships. The company’s employees worldwide are dedicated to building upon a rich heritage of medical breakthroughs, ensuring that Baxter continues to be at the forefront of healthcare advancements.
Baxter International (NYSE:BAX), a leading medtech company, is set to present at the Jefferies 2024 Global Healthcare Conference on June 5, 2024.
The presentation will be led by Joel Grade, Baxter's CFO, at 9:30 a.m. Eastern Time.
The event will be webcast live and accessible via Baxter's website, with a replay available until December 2, 2024.
Baxter International announced the mission and logo for its proposed kidney care and acute therapies company, Vantive. The mission, "Extending Lives, Expanding Possibilities," will guide Vantive in developing solutions for acute and chronic kidney diseases. The new logo, featuring a "V" motif in plum color, symbolizes the company's commitment to innovative therapies, digital solutions, and advanced services.
Vantive will build upon Baxter's nearly 70-year legacy in kidney care, aiming to improve outcomes for over one million patients annually across more than 70 countries. The separation of Vantive from Baxter's Renal Care and Acute Therapies businesses is expected to occur in the second half of 2024, either through a private equity sale or a public spinoff.
Baxter International Inc. (NYSE:BAX) has received FDA approval for an expanded indication for Clinolipid (Lipid Injectable Emulsion) for pediatric patients, including preterm and term neonates. Clinolipid provides essential fatty acids and calories for parenteral nutrition when oral or enteral nutrition is not possible. The approval highlights Baxter's commitment to meeting the nutritional needs of patients of all ages.
Baxter International Inc. (NYSE:BAX) will present at the Bank of America 2024 Health Care Conference with its chief financial officer, Joel Grade, scheduled to speak on May 15, 2024. The live webcast will be available for replay until August 14, 2024. Baxter is a global medtech leader offering a variety of healthcare products and solutions across the world.
Baxter International Inc. (NYSE:BAX) has declared a quarterly cash dividend of $0.29 per share of common stock, with an indicated annual dividend rate of $1.16 per share. The dividend will be payable on July 1, 2024, to stockholders of record as of May 31, 2024.
Baxter International Inc. reported first-quarter 2024 results with sales of $3.59 billion, up 2% on a reported basis and 3% on a constant currency basis, surpassing guidance. U.S. GAAP EPS was $0.07, adjusted EPS was $0.65. Full-year sales growth outlook is 2% (reported) and 2-3% (constant currency). Recent FDA clearance of Novum IQ large volume infusion pump and Dose IQ Safety Software. Baxter is focused on operational execution, innovation, and value creation for stakeholders.
FAQ
What is the current stock price of Baxter International (BAX)?
What is the market cap of Baxter International (BAX)?
What does Baxter International Inc. specialize in?
What was the impact of Baxter's acquisition of Hillrom?
What products does Baxter offer for kidney failure patients?
What are some of Baxter's injectable therapies?
What surgical products does Baxter provide?
What is Baxter's plan for its renal care segment?
How does Baxter contribute to global healthcare access?
How does Baxter ensure continuous innovation?
What are some of the digital solutions offered by Baxter?
What is Baxter's commitment to patient care?
